Jasper Therapeutics (NASDAQ:JSPR) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report released on Tuesday, Benzinga reports. They currently have a $65.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Stifel Nicolaus began coverage on Jasper Therapeutics in a research report on Thursday, June 27th. They issued a “buy” rating and a $86.00 price objective for the company. JMP Securities restated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Friday, September 27th. Royal Bank of Canada reduced their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. Finally, Evercore ISI reissued an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Monday, August 26th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $74.86.

Jasper Therapeutics Stock Up 1.1 %

JSPR opened at $20.04 on Tuesday. The stock’s 50 day moving average price is $19.11 and its two-hundred day moving average price is $21.48. The firm has a market capitalization of $301.88 million, a P/E ratio of -3.56 and a beta of 2.21. Jasper Therapeutics has a 12-month low of $4.00 and a 12-month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.12. As a group, analysts anticipate that Jasper Therapeutics will post -4.16 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in JSPR. StemPoint Capital LP bought a new position in shares of Jasper Therapeutics in the first quarter valued at approximately $3,794,000. Ikarian Capital LLC bought a new position in Jasper Therapeutics in the 1st quarter valued at $3,088,000. Russell Investments Group Ltd. acquired a new position in Jasper Therapeutics in the first quarter worth $2,343,000. Bank of New York Mellon Corp bought a new stake in shares of Jasper Therapeutics during the second quarter worth $740,000. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of Jasper Therapeutics during the first quarter worth $599,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.